Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Acute Myeloid Leukemias Clinical Trial

Official title: Transplantation of Hematopoetic Stem Cells and Infusion of CD56+CD3- NK Cells From Haploidentical Donors for Patients With Hematological Malignancies

Status Recruiting

Clinical Trial Summary

Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation. The effectiveness of allogeneic NK cells is a function of HLA-differences between donor and recipient that give rise to NK cell clones which do not express inhibitory receptors matching for the HLA molecules of the recipient. Aim of the study is to evaluate cellular therapy with alloreactive, IL-2 activated NK cells after transplantation of T-cell depleted stem cell grafts from one haplotype mismatched family donors in patients with hematological malignancies.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Myeloid Leukemias
• Advanced Hematological Malignancies
• Indication for Allogeneic Stem Cell Transplantation
• Leukemia, Myeloid, Acute
• Neoplasms
• no HLA-identical Donor Available

• NCT number: NCT01220544
• Study type: Interventional
• Source: Charite University, Berlin, Germany
• Contact: Lutz Uharek, MD
• Phone: +49308445
• Email: lutz.uharek@charite.de
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 2001
• Completion date: October 2011